Beginners’ Portfolio: GlaxoSmithKline plc Gains Ground, while BP plc And Barclays PLC Are Faltering

GlaxoSmithKline plc (LON: GSK), Barclays PLC (LON: BARC), and even BP plc (LON: BP) surely have a strong future.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, run as if based on real money with all costs, spreads and dividends accounted for. Transactions made for the portfolio are for educational purposes only and do not constitute advice to buy or sell.

It’s a couple of weeks since I last checked on the Beginners’ Portfolio, and prices have been going in both directions.

Paying dividends

There’s good news in that GlaxoSmithKline (LSE: GSK) shares have picked up since mid-January and now stand at 1,410p, although the share price is still down 6.4% since I first added them to the portfolio in June 2012. But to harp on about the importance I place in solid dividends, our investment in Glaxo is actually 12% up once the annual cash payments have been included, and that’s after accounting for all costs and spreads.

Now, 12% in a bit less than four years is a poor return, but it still beats cash left sitting in a bank account. We have a dividend yield of 6.2% forecast for 2016 after the firm confirmed its 2015 yield of 5.8%. And what’s more, we really should be on the cusp of a return to earnings growth — if we see a forecast uptick for 2017, I’d expect the share price to start moving upwards. GlaxoSmithKline is a firm hold.

Oily loser

The price fall for BP (LSE: BP) after its weak full-year results on 3 February was perhaps understandable, but we’ve actually seen a slight uptick since then, to 355p as I write. It’s all about the price of oil, clearly, and Brent Crude is up from a low of below $30 a barrel to a shade under $35 today. But what bemuses me is that BP’s long-term prospects actually have very little correlation to the short-term price of oil, especially as the current excess of supply just has to fade as so many producers are losing money at today’s prices.

Almost everyone expects oil to recover substantially by the end of 2016, and if and when that happens, BP shares will benefit accordingly. In the meantime, we have a forecast dividend yield of 7% on the cards — it won’t be covered, but BP should be able to pay it from cash comfortably. And it’s those dividends that, once again, have partly saved the Beginners’ investment.

I bought not long after the Deepwater Horizon disaster, and my timing was poor — the pain of that turned out worse than I expected. And that was followed by the oil price crash. But what really surprises me is that, despite all the woes, our BP investment is only down 3.7% once dividends are included (and after deducting all costs). And that underlines to me just how safe our big oil companies are, not risky.

Falling banks

Barclays (LSE: BARC) shares have picked up a bit in recent days, but they’re still on a longer-term slide as confidence remains elusive and fear spreads its diabolical wings. With the price at 173p today, we’re actually down 32% on Barclays since adding to the portfolio two years ago in February 2014. Back then I thought Barclays was solid and had a great chance of recovery.

Since then? Well, I simply see Barclays as an even better buy now. Predicted dividend yields are relatively modest at around 2.9% for the year just ended, followed by a forecast 3.6% in 2016. But with earnings growth firmly on the way back, we’re looking at a forecast P/E of only 8.6 for the year ahead.

Never mind hold or buy, I see Barclays as a steal.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The FTSE 100 reaches an all-time high! Here are 2 of its best stocks to consider buying

With the FTSE 100 soaring in 2024, this Fool thinks investors should consider buying these two stocks. Here he breaks…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Here’s why I see cheap UK shares soaring in the years ahead

UK shares look undervalued and this Fool plans to take advantage of it. Here he details one stock he's keen…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Dividend Shares

Is Legal & General the best stock to buy in the FTSE right now?

UK investors have been piling into Legal & General in recent weeks. But are there better FTSE shares to buy…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With no savings at 40, I’d buy and hold these 2 FTSE 250 stocks to retirement

Jon Smith outlines two FTSE 250 stocks that he believes offer long-term value for an investors that's looking to build…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,000 in savings? Here’s how I’d try to turn that into £7,864 every year in passive income

Investing a relatively small amount in high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Is Aviva’s share price a bargain now it’s trading well below £5?

Aviva’s share price has slumped to well below £5, but even before that it looked a bargain to me, with…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Rolls-Royce shares: tapped out at £4 or poised to climb further?

Rolls-Royce shares are finally showing signs of faltering after months of gains. Can they still climb further or is a…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Up 30%, this FTSE 100 stock has been my best buy in 2024

I’m considering the prospects of my best-performing FTSE 100 stock this year. Can this major UK bank continue to make…

Read more »